A chimeric alphavirus RNA replicon gene-based vaccine for human parainfluenza virus type 3 induces protective immunity against intranasal virus challenge

Vaccine

Volumn 25, Issue 3, 2007, Pages 481-489

  Greer, Catherine E ^a   Zhou, Fengmin ^a   Legg, Harold S ^a   Tang, Zequn ^a   Perri, Silvia ^a   Sloan, Barbara A ^a   Megede, Jan zur ^a   Uematsu, Yasushi ^a   Vajdy, Michael ^a   Polo, John M ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Alphavirus; PIV3; Vaccine

Indexed keywords

HN PROTEIN; NEUTRALIZING ANTIBODY; VACCINE;

ALPHA VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BACTERIAL IMMUNITY; CONTROLLED STUDY; FEMALE; HAMSTER; IMMUNOGENICITY; MOUSE; NEWBORN; NONHUMAN; PARAINFLUENZA VIRUS 3; PRIORITY JOURNAL; REPLICON; RNA VECTOR; TURBINATE; VIRUS EXPRESSION; VIRUS GENE; VIRUS INFECTION; VIRUS PARTICLE; VIRUS REPLICATION;

ADMINISTRATION, INTRANASAL; ALPHAVIRUS; ANIMALS; ANTIBODIES, VIRAL; CRICETINAE; ENCEPHALITIS VIRUS, VENEZUELAN EQUINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; MESOCRICETUS; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; PARAINFLUENZA VACCINES; PARAINFLUENZA VIRUS 3, HUMAN; PARAMYXOVIRIDAE INFECTIONS; REPLICON; RNA, VIRAL; SINDBIS VIRUS; VACCINES, SYNTHETIC;

EID: 33845205167     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.07.048     Document Type: Article

References (66)

1. Glezen W.P., and Denny F.W. Parainfluenza viruses. In: Evans A.C., and Kaslow D. (Eds). Viral Infections in humans: epidemiology and control (1997), Plenum, New York 551-567
2. Chanock R.M., Murphy B.R., and Collins P.L. Parainfluenza viruses. In: Knipe D.M. (Ed). Fields virology vol. 1 (2001), Lippincott Williams & Wilkins, Philadelphia, PA 1341-1379
3. Chin J., Magoffin R.L., Shearer L.A., Schieble J.H., and Lennette E.H. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 89 (1969) 449-463
4. Fulginiti V.A., Eller J.J., Sieber O.F., Joyner J.W., Minamitani M., and Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 89 4 (1969) 435-448
5. Kapikian A.Z., Mitchell R.H., Chanock R.M., Shvedoff R.A., and Stewart C.E. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 89 (1969) 405-421
6. Ottolini M.G., Porter D.D., Hemming V.G., and Prince G.A. Enhanced pulmonary pathology in cotton rats upon challenge after immunization with inactivated parainfluenza virus 3 vaccines. Viral Immunol 13 2 (2000) 231-236
7. Belshe R.B., and Hissom F.K. Cold adaptation of parainfluenza virus type 3: induction of three phenotypic markers. J Med Virol 10 4 (1982) 235-242
8. Skiadopoulos M.H., Durbin A.P., Tatem J.M., Wu S.L., Paschalis M., Tao T., et al. Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes. J Virol 72 3 (1998) 1762-1768
9. Schmidt A.C., McAuliffe J.M., Huang A., Surman S.R., Bailly J.E., Elkins W.R., et al. Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates. J Virol 74 19 (2000) 8922-8929
10. Skiadopoulos M.H., Tao T., Surman S.R., Collins P.L., and Murphy B.R. Generation of a parainfluenza virus type 1 vaccine candidate by replacing the HN and F glycoproteins of the live-attenuated PIV3 cp45 vaccine virus with their PIV1 counterparts. Vaccine 18 5-6 (1999) 503-510
11. Coelingh K.J., Winter C.C., Murphy B.R., Rice J.M., Kimball P.C., Olmsted R.A., et al. Conserved epitopes on the hemagglutinin-neuraminidase proteins of human and bovine parainfluenza type 3 viruses: nucleotide sequence analysis of variants selected with monoclonal antibodies. J Virol 60 1 (1986) 90-96
12. van Wyke Coelingh K.L., Winter C.C., Tierney E.L., London W.T., and Murphy B.R. Attenuation of bovine parainfluenza virus type 3 in nonhuman primates and its ability to confer immunity to human parainfluenza virus type 3 challenge. J Infect Dis 157 4 (1988) 655-662
13. Haller A.A., Miller T., Mitiku M., and Coelingh K. Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector. J Virol 74 24 (2000) 11626-11635
14. Spriggs M.K., Murphy B.R., Prince G.A., Olmsted R.A., Collins P.L., Haller A.A., et al. Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity. J Virol 61 11 (1987) 3416-3423
15. Durbin A.P., Cho C.J., Elkins W.R., Wyatt L.S., Moss B., and Murphy B.R. Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies. J Infect Dis 179 6 (1999) 1345-1351
16. Durbin A.P., Wyatt L.S., Siew J., Moss B., and Murphy B.R. The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys. Vaccine 16 13 (1998) 1324-1330
17. Wyatt L.S., Shors S.T., Murphy B.R., and Moss B. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 14 15 (1996) 1451-1458
18. Ebata S.N., Prevec L., Graham F.L., and Dimock K. Function and immunogenicity of human parainfluenza virus 3 glycoproteins expressed by recombinant adenoviruses. Virus Res 24 1 (1992) 21-33
19. Ebata S.N., Cote M.J., Kang C.Y., and Dimock K. The fusion and hemagglutinin-neuraminidase glycoproteins of human parainfluenza virus 3 are both required for fusion. Virology 183 1 (1991) 437-441
20. Kobinger G.P., Feldmann H., Zhi Y., Schumer G., Gao G., Feldmann F., et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology 346 2 (2006) 394-401
21. Barouch D.H., Pau M.G., Custers J.H., Koudstaal W., Kostense S., Havenga M.J., et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 172 10 (2004) 6290-6297
22. Sharpe S., Polyanskaya N., Dennis M., Sutter G., Hanke T., Erfle V., et al. Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity. J Gen Virol 82 Pt 9 (2001) 2215-2223
23. Lodmell D.L., and Ewalt L.C. Rabies vaccination: comparison of neutralizing antibody responses after priming and boosting with different combinations of DNA, inactivated virus, or recombinant vaccinia virus vaccines. Vaccine 18 22 (2000) 2394-2398
24. Polo J.M., and Dubensky T.W. Virus-based vectors for human vaccine applications. Drug Discov Today 7 13 (2002) 719-727
25. Xiong C., Levis R., Shen P., Schlesinger S., Rice C.M., and Huang H.V. Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science 243 4895 (1989) 1188-1191
26. Polo J.M., Belli B.A., Driver D.A., Frolov I., Sherrill S., Hariharan M.J., et al. Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors. Proc Natl Acad Sci USA 96 8 (1999) 4598-4603
27. Pushko P., Parker M., Ludwig G.V., Davis N.L., Johnston R.E., and Smith J.F. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239 2 (1997) 389-401
28. Liljestrom P., and Garoff H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (NY) 9 12 (1991) 1356-1361
29. Bredenbeek P.J., Frolov I., Rice C.M., and Schlesinger S. Sindbis virus expression vectors: packaging of RNA replicons by using defective helper RNAs. J Virol 67 11 (1993) 6439-6446
30. Leitner W.W., Hwang L.N., Bergmann-Leitner E.S., Finkelstein S.E., Frank S., and Restifo N.P. Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines. Vaccine 22 11-12 (2004) 1537-1544
31. MacDonald G.H., and Johnston R.E. Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J Virol 74 2 (2000) 914-922
32. Gardner J.P., Frolov I., Perri S., Ji Y., MacKichan M.L., zur Megede J., et al. Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein. J Virol 74 24 (2000) 11849-11857
33. Perri S., Greer C.E., Thudium K., Doe B., Legg H., Liu H., et al. An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol 77 19 (2003) 10394-10403
34. Stokes A., Tierney E.L., Murphy B.R., and Hall S.L. The complete nucleotide sequence of the JS strain of human parainfluenza virus type 3: comparison with the Wash/47885/57 prototype strain. Virus Res 25 1-2 (1992) 91-103
35. Olivo P.D., Frolov I., and Schlesinger S. A cell line that expresses a reporter gene in response to infection by Sindbis virus: a prototype for detection of positive strand RNA viruses. Virology 198 1 (1994) 381-384
36. Newman J.T., Riggs J.M., Surman S.R., McAuliffe J.M., Mulaikal T.A., Collins P.L., et al. Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses. J Virol 78 4 (2005) 2017-2028
37. van Wyke Coelingh K.L., Winter C.C., Tierney E.L., Hall S.L., London W.T., Kim H.W., et al. Antibody responses of humans and nonhuman primates to individual antigenic sites of the hemagglutinin-neuraminidase and fusion glycoproteins after primary infection or reinfection with parainfluenza type 3 virus. J Virol 64 8 (1990) 3833-3843
38. van Wyke Coelingh K.L., Winter C., and Murphy B.R. Antigenic variation in the hemagglutinin-neuraminidase protein of human parainfluenza type 3 virus. Virology 143 2 (1985) 569-582
39. Frey S., Poland G., Percell S., and Podda A. Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults. Vaccine 21 27-30 (2003) 4234-4237
40. Buthala D.A., and Soret M.G. Parainfluenza Type 3 Virus Infection in Hamsters: Virologic, Serologic, and Pathologic Studies. J Infect Dis 114 (1964) 226-234
41. Collier A.M., and Clyde Jr. W.A. Model systems for studying the pathogenesis of infections causing bronchiolitis in man. Pediatr Res 11 3 Pt 2 (1977) 243-246
42. O'Hagan D.T., Ott G.S., and Van Nest G. Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. Mol Med Today 3 (1997) 69-75
43. Clements M.L., Belshe R.B., King J., Newman F., Westblom T.U., Tierney E.L., et al. Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees. J Clin Microbiol 29 6 (1991) 1175-1182
44. Karron R.A., Belshe R.B., Wright P.F., Thumar B., Burns B., Newman F., et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatr Infect Dis J 22 5 (2003) 394-405
45. Wright P.F., Karron R.A., Belshe R.B., Thompson J., Crowe Jr. J.E., Boyce T.G., et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 182 5 (2000) 1331-1342
46. Belshe R.B., Newman F.K., Tsai T.F., Karron R.A., Reisinger K., Roberton D., et al. Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old. J Infect Dis 189 3 (2004) 462-470
47. Belshe R.B., Newman F.K., Anderson E.L., Wright P.F., Karron R.A., Tollefson S., et al. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children. J Infect Dis 190 12 (2004) 2096-2103
48. Karron R.A., Wright P.F., Hall S.L., Makhene M., Thompson J., Burns B.A., et al. A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children. J Infect Dis 171 5 (1995) 1107-1114
49. Karron R.A., Makhene M., Gay K., Wilson M.H., Clements M.L., and Murphy B.R. Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants. Pediatr Infect Dis J 15 8 (1996) 650-654
50. Berglund P., Quesada-Rolander M., Putkonen P., Biberfeld G., Thorstensson R., and Liljestrom P. Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res Hum Retroviruses 13 17 (1997) 1487-1495
51. Vajdy M., Veazey R., Tham I., deBakker C., Westmoreland S., Neutra M., et al. Early immunologic events in mucosal and systemic lymphoid tissues after intrarectal inoculation with simian immunodeficiency virus. J Infect Dis 184 8 (2001) 1007-1014
52. Gupta S., Janani R., Bin Q., Luciw P., Greer C.E., Perri S., et al. Characterization of HIV-gag-specific IFNg-expressing cells following protective mucosal immunization with alphavirus replicon particles. J Virology 79 11 (2005) 7135-7145
53. Davis N.L., West A., Reap E., MacDonald G., Collier M., Dryga S., et al. Alphavirus replicon particles as candidate HIV vaccines. IUBMB Life 53 4-5 (2002) 209-211
54. Polo J.M., Belli B.A., Driver D.A., Sherrill S., Hariharan M.J., Townsend K., et al. Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors. Proc Natl Acad Sci USA 96 (1999) 4598-4603
55. Chen M., Hu K.F., Rozell B., Orvell C., Morein B., and Liljestrom P. Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus. J Immunol 169 6 (2002) 3208-3216
56. Fleeton M.N., Chen M., Berglund P., Rhodes G., Parker S.E., Murphy M., et al. Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus. J Infect Dis 183 9 (2001) 1395-1398 [Epub 2001 Mar 1330]
57. Pan C.H., Valsamakis A., Colella T., Nair N., Adams R.J., Polack F.P., et al. Inaugural Article: Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles. Proc Natl Acad Sci USA 102 33 (2005) 11581-11588
58. Pushko P., Parker M., Ludwig G.V., Davis N.L., Johnston R.E., and Smith J.F. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239 2 (1997) 389-401
59. Eralp Y., Wang X., Wang J.P., Maughan M.F., Polo J.M., and Lachman L.B. Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Breast Cancer Res 6 4 (2004) 275-283
60. Daemen T., Pries F., Bungener L., Kraak M., Regts J., and Wilschut J. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7. Gene Ther 7 21 (2000) 1859-1866
61. Cheng W.F., Hung C.F., Hsu K.F., Chai C.Y., He L., Polo J.M., et al. Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum Gene Ther 13 4 (2002) 553-568
62. Velders M.P., McElhiney S., Cassetti M.C., Eiben G.L., Higgins T., Kovacs G.R., et al. Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. Cancer Res 61 21 (2001) 7861-7867
63. Vajdy M., Gardner J., Neidleman J., Cuadra L., Greer C., Perri S., et al. Human immunodeficiency virus type 1 Gag-specific vaginal immunity and protection after local immunizations with sindbis virus-based replicon particles. J Infect Dis 184 12 (2001) 1613-1616
64. Skiadopoulos M.H., Surman S.R., Riggs J.M., Orvell C., Collins P.L., and Murphy B.R. Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins. Virology 297 1 (2002) 136-152
65. Tao T., Skiadopoulos M.H., Durbin A.P., Davoodi F., Collins P.L., and Murphy B.R. A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge. Vaccine 17 9-10 (1999) 1100-1108
66. Haller A.A., Mitiku M., and MacPhail M. Bovine parainfluenza virus type 3 (PIV3) expressing the respiratory syncytial virus (RSV) attachment and fusion proteins protects hamsters from challenge with human PIV3 and RSV. J Gen Virol 84 Pt 8 (2003) 2153-2162